CXCR2 and cancer: From our own findings and prior reports of CXCLs-CXCR2 in cancer progression [24], we hypothesized that MIF/CXCLs-CXCR2 pathways could be activated by TKI-treatment in viable blasts to support their survival and continuous proliferation.